FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
News|Articles|October 8, 2026
September 2026 retina recap: Pivotal readouts and the MOGENRY BLA
Author(s)Kassi Filkins
Pivotal wet AMD, DME, and XLRP readouts; the MOGENRY BLA; and Retina Society, EURETINA, and ESCRS highlights from September.
Advertisement
Advertisement
September was a readout month for retina. Without a single FDA approval in the specialty, the news was driven by topline phase 3 data in wet AMD and DME, a pivotal gene therapy win in X-linked retinitis pigmentosa (XLRP), and the Retina Society 59th Annual Scientific Meeting in Los Angeles (September 23 to 26), where several programs presented their first or longest-term data. The BLA acceptance for
Related to this article
Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.
Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.
CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.
Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.
A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.
Advertisement
Advertisement